Metraipolis › archive › dc_207f2007b569
Safety of liposomal daunorubicin-cytarabine (CPX-351) in secondary AML: Japanese phase 1/2 study and global phase 3 study — Europe PMC PMID:40815417
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40815417
- DOI
- 10.1007/s12185-[numero omesso]-4
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-10T14:21:03.681Z
- SHA-256 of the archived text
0f04c5748e342c6909a124f48dc77e7824e4d302ccdd5a5258bc9e3abeb18aab- Stable URL of this page
https://metraipolis.com/documento/dc_207f2007b569
How to cite
Safety of liposomal daunorubicin-cytarabine (CPX-351) in secondary AML: Japanese phase 1/2 study and global phase 3 study — Europe PMC PMID:40815417 — Europe PMC (en), https://europepmc.org/article/MED/40815417 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_207f2007b569 (Metraipolis archive dc_207f2007b569, sha256 0f04c5748e342c6909a124f48dc77e7824e4d302ccdd5a5258bc9e3abeb18aab)
BibTeX
@misc{dc207f2007b569,
title = {Safety of liposomal daunorubicin-cytarabine (CPX-351) in secondary AML: Japanese phase 1/2 study and global phase 3 study — Europe PMC PMID:40815417},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40815417},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_207f2007b569; sha256 0f04c5748e342c6909a124f48dc77e7824e4d302ccdd5a5258bc9e3abeb18aab},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40815417. Agents can read the archived copy with the MCP tool read_document.